Orimelan (Melatonin)

Melatonin, the active ingredient in Orimelan, is a naturally occurring hormone presented as an oral tablet for oral administration. It assists in regulating the sleep‑wake cycle and is used to promote sleep in adults with insomnia or other circadian rhythm disturbances.

GNH USA supplies Orimelan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product is available over the counter in the EU and follows strict quality standards. It is manufactured under GMP conditions to ensure purity and consistency.

Orimelan (melatonin) is used to address sleep‑related conditions by influencing the body's circadian signaling pathways.

Insomnia: helps initiate and maintain sleep in adults with difficulty falling asleep. Jet lag: reduces the time needed to adjust to new time zones after travel. Shift work disorder: improves sleep quality for individuals working non‑standard hours.

Orimelan may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Drowsiness - Headache - Dizziness - Nausea

Serious or Rare Side Effects: - Allergic reaction (rash, itching, swelling) - Severe hypotension - Mood changes or depression

When using Orimelan, consider the following precautions to ensure safe and effective use.

Consult healthcare provider before use: especially if pregnant, nursing, or having chronic medical conditions. Avoid operating machinery or driving if drowsy: melatonin can cause residual sedation. Do not combine with other sedatives without medical advice: risk of excessive CNS depression. Use caution in patients with depression or mood disorders: melatonin may affect mood. Store at ambient temperature: keep in the original container, protect from moisture and light.

Orimelan can interact with other medicines, requiring attention to avoid adverse effects.

Major Interactions (Avoid): - Alcohol: may increase sedation and impair alertness. - Benzodiazepines or other CNS depressants: additive sedative effect can be hazardous.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., SSRIs, MAOIs): may alter sleep architecture; monitor response. - Anticoagulants (e.g., warfarin): melatonin may affect platelet aggregation; check coagulation parameters. - CYP1A2 inhibitors (e.g., fluvoxamine): can raise melatonin plasma levels; adjust if needed.